How to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxinA by unknown
Cite as
Przydacz M, Golabek T, Chlosta P. How to assess and predict 
success or failure of intra-detrusor injections with 





© 2019 by Wroclaw Medical University 
This is an article distributed under the terms of the 









Received on February 5, 2018
Reviewed on May 2, 2018
Accepted on May 5, 2018
Published online on February 5, 2019
Abstract
Intra-detrusor injection therapy with onabotulinumtoxinA is generally accepted as a highly effective, minimally 
invasive and well-tolerated day procedure for patients with refractory overactive bladder (OAB) and neu-
rogenic detrusor overactivity (NDO). The aim of this study was to summarize currently available methods 
of assessing treatment efficacy and risk factors that may influence the therapeutic effect of this approach. 
We found that there are discrepancies in the assessment methods. The evaluation of intra-detrusor injections 
with onabotulinumtoxinA in clinical trials are not always transposable into day-to-day practice. Moreover, 
the primary endpoints in clinical trials do not explore the entirety of meaningful patient-centered outcomes. 
Therefore, in daily clinical practice with patients with overactive bladder syndrome, the therapy should be 
assessed with objective measures (bladder diaries) and patient-oriented outcomes analyzing the quality 
of life (questionnaires). In neurogenic individuals, therapeutic efficacy should be additionally evaluated with 
urodynamic studies. Potential risk factors that may influence the treatment outcomes include urodynamically 
proven detrusor overactivity, elevated maximum detrusor pressure, greater maximum cystometric capacity, 
impaired bladder compliance, older age, male gender, a higher baseline bother score, previous anticholinergic 
treatment, and repeated injections with a subsequent decline in efficacy. The risk of intermittent catheter-
ization following injections seems to depend on the etiology of detrusor overactivity, the injected dose, 
the injection technique, and the definition of significant post-void residual urine requiring catheterization.
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Intra-detrusor injection therapy with onabotulinum-
toxinA (Botox®; Allergan Inc., Irvine, USA) is  gener-
ally accepted as  a highly effective, minimally invasive 
and well-tolerated day procedure for patients suffering 
from refractory overactive bladder (OAB) and neurogenic 
detrusor overactivity (NDO). Its efficacy has been widely 
investigated and proven in systematic reviews with meta-
analyses of randomized, double-blind, placebo-controlled 
multicenter trials,1–3 and onabotulinumtoxinA is currently 
recommended by the leading urological societies for both 
neurogenic and non-neurogenic voiding dysfunctions.4 
Treatment with onabotulinumtoxinA in patients suffering 
from OAB mainly improves their quality of life and reduc-
es incontinence, while in those with NDO it additionally 
helps preserve renal function.
OnabotulinumtoxinA, a specific formulation of botu-
linum toxin, is a neuromodulator that directly inhibits 
efferent acetylcholine-mediated detrusor contractions 
and reduces muscle spasticity.3 This therapy also has other 
mechanisms of action, and inhibits the release of different 
vesicle-mediated neurotransmitters responsible for inap-
propriate afferent signaling from an overactive detrusor, 
including effects on afferent sensory neurons via TRPV1 
and P2X3 receptors. Therefore, the ability of onabotu-
linumtoxinA to synergistically target the afferent and ef-
ferent neuronal pathways of bladder control may explain 
the  profound effect observed on  urgency, frequency 
and urgency incontinence, as well as the failure of prior an-
ticholinergic therapy. Consequently, onabotulinumtoxinA 
offers a  complex inhibitory effect on  multiple targets 
in the bladder wall that may cause OAB and NDO.
It is of utmost importance to identify patients in whom 
intra-detrusor Botox® therapy has failed to help or who 
may not benefit from it. However, appropriate patient en-
rollment and assessment of treatment success/failure may 
be challenging for physicians, as these are generally based 
on subjective outcomes. There is no single study summa-
rizing currently available assessment methods of therapy 
success/failure and predicting factors for this treatment. 
Recognition of predictors is a prerequisite for an individu-
alized approach, and adequate knowledge could help clini-
cians avoid ineffective procedures and potential treatment-
related adverse effects. Furthermore, assessment methods 
of response/non-response to the treatment have important 
applications in future research. Therefore, the aim of this 
review is to summarize methods of assessing the success/
failure of the therapy and to present a list of risk factors 
that may influence the outcomes of intra-detrusor injec-
tions of onabotulinumtoxinA.
Material and methods
Maximum data were collected according to different 
methods, including searches with multiple and specific 
keywords and reference checks. Our searches targeted 
the terms “neurogenic bladder”, “neurogenic lower urinary 
tract dysfunction”, “overactive bladder”, “onabotulinum-
toxinA”, “success”, “failure”, and “risk factors”. We searched 
PubMed (including MEDLINE and  PubMed Central), 
the Cochrane Library and the Web of Science databases. 
During full-text screening, references in pertinent papers 
were checked manually to identify other related papers. 
In order to present reliable assessment methods of treat-
ment success/failure, only randomized double-blind 
placebo-controlled trials were included. They were also 
selected from currently available systematic reviews with 
meta-analyses of OAB and NDO to avoid omitting impor-
tant trials.1–3,5–11 The reports on risk factors that we found 
(searching through all the available literature) were ana-
lyzed with a modified version of the Oxford grading sys-
tem for recommendations, using levels of evidence (LE) 
and grades of recommendation (GR).12 
Results
Assessment methods
There is no consensus among researchers how to as-
sess the success/failure of treatment with onabotulinum-
toxinA injections. To make matters even more complex, 
most of the randomized clinical trials on OAB and NDO 
used either objective measures from bladder diaries, sub-
jective patient-reported outcomes from questionnaires 
or urodynamic-related parameters as primary experimen-
tal outcomes.
Overactive bladder
Overactive bladder can be debilitating for  patients, 
and  may have a  profound negative impact on  the  pa-
tient’s quality of life. Oral anticholinergics are the main-
stay of first-line pharmacologic treatment,4 but may be 
associated with unwanted side effects including dry 
mouth, constipation and blurred vision, leading to poor 
compliance and  a  high discontinuation rate in  clini-
cal practice. Therefore, minimally invasive treatment 
with onabotulinumtoxinA offers an effective alternative 
to other minimally invasive therapies such as neuromod-
ulation, as well as to invasive surgical bladder augmen-
tation. Our study revealed that there is no homogeneity 
among randomized clinical trials in reporting outcomes. 
Detailed comparisons between published randomized 
placebo-controlled trials are hampered by  differences 
in the outcome measures used, whether diary data were 
compared daily or weekly, and the fact that studies re-
cruited both men and women. Clinicians should also keep 
in mind that our current knowledge regarding the effi-
cacy of  the  treatment is  limited to patients with OAB 
wet (i.e., OAB with concomitant urinary incontinence). 
There is a paucity of reliable data analyzing treatment 
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with onabotulinumtoxinA in individuals suffering from 
OAB without urinary incontinence (OAB dry), who com-
prise approx. 2/3 of all OAB patients.13
To date, 9 randomized placebo-controlled clinical tri-
als have been conducted in order to evaluate the efficacy 
of onabotulinumtoxinA in OAB.14–25 A summary of the pa-
tients included, the doses evaluated and primary and sec-
ondary experimental outcomes is presented in Table 1. 
The most common primary experimental outcome, used 
in 4 studies, has been defined as a change from baseline 
in the number of urgency urinary incontinence episodes. 
Three of these studies used an additional co-primary out-
come, defined as the proportion of patients with a positive 
treatment response on the 4-score Treatment Benefit Scale 
(2 studies) and symptom scores assessed with a validated 
questionnaire (1 study). One study used a change from 
baseline in urinary frequency per 24 h as a primary ex-
perimental outcome, 1 study evaluated time to treatment 
failure (defined as a score of 4 or greater on the Patient 
Global Impression of Improvement) and 1 used the pro-
portion of patients showing >50% improvement compared 
to baseline of both urgency and urgency urinary inconti-
nence episodes. Two studies mainly based their analyses 
on urodynamic parameters and used maximum cystomet-
ric capacity as a primary experimental outcome.
A time analysis of the studies included showed that the ef-
fects of onabotulinumtoxinA are commonly perceived be-
tween 3 days and 2 weeks after injection.14,17,22,24 Although 
the mean duration of onabotulinumtoxinA-related improve-
ment is approx. 9–10 months,14,15 the efficacy of the therapy 
should be assessed between weeks 4 and 12, as some ex-
perimental outcomes have been shown to become insig-
nificant, with decreasing treatment response compared 
with a placebo after 12 weeks (symptom reduction benefits 
typically show a slight trend towards decrease after 20–24 
weeks).14,17,18,23,24 In patients with more severe OAB at base-
line (i.e., more than 8 episodes of incontinence per day), 
efficacy should be assessed no sooner than 6 weeks after 
injection.16
Neurogenic detrusor overactivity
Neurogenic detrusor overactivity is one of  the most 
challenging problems in urology. Various disorders or in-
juries affecting the central nervous system (e.g., stroke, 
Parkinson disease and multiple sclerosis) may cause this 
chronic dysfunction, in which the bladder becomes overac-
tive and empties too frequently/quickly. The primary goals 
of treatment for NDO are to protect the upper urinary 
tract by decreasing bladder pressure, reducing inconti-
nence and improving quality of life. Initial NDO treatment 
consists of anticholinergics, often with clean intermit-
tent catheterization (CIC). However, long-term treatment 
may be suboptimal, with patients stopping medication due 
to a lack of efficacy and bothersome side effects, similar 
to those with OAB. Minimally invasive treatment with 
onabotulinumtoxinA has been of benefit to those patients, 
as it induces paralysis of the detrusor muscle and conse-
quently results in a decreased risk of vesicoureteral reflux, 
preventing upper urinary tract deterioration and possible 
kidney damage.
To date, 6 randomized placebo-controlled clinical tri-
als have evaluated the efficacy of  intra-detrusor injec-
tions of onabotulinumtoxinA in neurogenic patients.26–34 
These studies mainly included patients with spinal cord 
injuries or with multiple sclerosis. All of these studies used 
a change from baseline in the number of urgency urinary 
incontinence episodes per week as the primary experi-
mental outcome. Five of the studies assessed this primary 
experimental outcome at week 6.
Improvements usually occur starting from week 2 
and are maintained for the duration of 24 weeks of follow-
up.27,30–34 In 3 studies with an open-label phase and longer 
follow-up, the median duration of the effect – the time 
lapse before patient-requested retreatment – was 36, 42.1 
and 60 weeks, respectively.28,29,31 These benefits reached 
their maximum between the 2nd and 6th week.10 Approxi-
mately 60% of the patients may maintain the treatment 
effect for  up to  9 months.34 However, some of  the  ef-
ficacy parameters tend to  become insignificant after 
18–24 weeks26,28 and efficacy evaluation before 6 weeks 
may be too early for reliable assessment.34
Risk factors for treatment failure
Detrusor overactivity
Detrusor overactivity has been defined as the presence 
of involuntary detrusor contractions during the filling phase 
of urodynamics. Whereas in neurogenic individuals urody-
namically proven detrusor overactivity is necessary to es-
tablish a diagnosis of NDO, in those with OAB, although 
common, it is not present in all patients and not required 
for an OAB diagnosis.
The impact of detrusor overactivity on the final effect 
of treatment with onabotulinumtoxinA in OAB patients 
is still under debate, as the majority of available studies re-
quired detrusor overactivity for inclusion. Dowson et al. con-
ducted a randomized controlled trial examining the effects 
of onabotulinumtoxinA exclusively in patients with OAB 
without concomitant detrusor overactivity (LE 1, GR  B).21 
The trial was halted after the recruitment of 23 patients 
as a result of poorly perceived patient benefit and no clini-
cal benefit, with no  change observed in  the  symptom 
score and quality of  life for  the majority of  the partici-
pants. Individually, only 2 patients in the treatment arm 
of the study derived any benefit from the injections, whereas 
the remainder experienced no change in their symptoms. 
Of note, the study enrolled only 1/3 of the patients sug-
gested by the power calculation, and the primary endpoint 
(maximum cystometric capacity) was statistically signifi-
cant. In a large randomized placebo-controlled clinical trial 
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by Dmochowski et al. (n = 313; LE 1, GR B/C), a subgroup 
analysis for patients with and without detrusor overactivity 
showed that the patient-reported outcomes were similar 
in the 2 groups, although statistical significance in com-
parison with the placebo was not reached in these much 
smaller subgroups.17 Further analysis of the urodynamic 
data also demonstrated that patients with detrusor overac-
tivity at baseline experienced treatment efficacy compared 
to those without it.18 The authors proposed that  urodynamic 
confirmation of  detrusor overactivity before treatment 
may not be predictive in determining treatment success, 
as patients with OAB with and without detrusor overactiv-
ity benefited from the treatment. These results are in line 
with those presented by Schmid et al. from an open-label 
study (n = 100; LE 2, GR C).35 Although the last 2 trials 
demonstrated some clinical improvement in patients with 
and without detrusor overactivity, physicians should keep 
in mind that they were not specifically designed to examine 
the influence of detrusor overactivity on treatment out-
comes and the data presented may be inconsistent.
Maximum detrusor pressure
There have been 2 OAB studies evaluating the influence 
of elevated maximum detrusor pressure on final treatment 
outcomes. Sahai et al., in a subanalysis of urodynamic data 
from their randomized clinical trial (LE 1, GR B/C), reported 
that very high maximum detrusor pressure (>110 cm H2O) 
may predict a poor response to treatment with 200 U of ona-
botulinumtoxinA (sensitivity 0.86; specificity 1.0), indicat-
ing that higher doses may be necessary in these patients.36 
In turn, Rovner et al. demonstrated that elevated maximum 
detrusor pressure is a poor indicator of treatment response 
(LE 1, GR B/C).18 Similarly to Sahai et al., their analysis was 
based on urodynamic data from a previously published 
randomized clinical trial. It is noteworthy that in the study 
by Rovner et al., the mean baseline maximum detrusor pres-
sure ranged from 21.7 cm H2O (SD ±18.26) to 24.3 cm H2O 
(SD ±18.40), whereas in the study by Sahai et al. it was 
much higher, ranging from 74.4  cm  H2O (SD  ±32.6) 
to 138.0 cm H2O (SD ±30.7).
In a retrospective analysis of 292 neurogenic patients 
monitored up to 7 years, high maximum detrusor pressure 
has been identified as a risk factor of treatment failure. 
(LE 3, GR C).37 Nevertheless, the multivariate analysis 
failed to confirm it as an independent long-term risk 
factor.
Maximum cystometric capacity
A prospective study by Álvares et al. on individuals who 
had suffered spinal cord injury (n = 34) showed that pa-
tients with greater maximum cystometric capacity re-
sponded significantly better than others (LE 2, GR B/C).38 
The authors also demonstrated that cystography param-
eters, including bladder shape, capacity and the presence 
of diverticula, were not significantly different between 
responders and non-responders to the therapy.
Bladder compliance
It has been suggested that pre-existing bladder wall 
fibrosis may limit therapeutic efficacy. The  impact 
of bladder compliance on treatment results was assessed 
by Schmid et al. in their prospective non-randomized 
study.35 A total of 23 men and 77 women with OAB were 
consecutively treated with injections of 100 U onabotu-
linumtoxinA and then followed up with urodynamics 
at 4, 12 and 36 weeks. Treatment failed in 8 patients, all 
of whom had low bladder compliance (less than 10 mL/cm 
H2O) and  maximum cystometric capacity less than 
100 mL due to bladder wall fibrosis (LE 2, GR B). These re-
sults are in line with those presented by Kim et al. in neu-
rogenic patients.39 Preoperative bladder compliance was 
significantly lower in non-responders to onabotulinum-
toxinA injections (25.11 ±32.59 vs 8.64 ±6.52; p = 039). 
Furthermore, a  regression analysis revealed that  de-
creased bladder compliance (<10 mL/cm H2O; odds ratio 
(OR) = 6.041; 95% confidence interval (CI) = 1.189–30.677; 
p = 0.030) was an independent predictor of poor response 
(LE 3, GR C). A long-term study with a 7-year follow-up 
of neurogenic patients confirmed in a univariate analysis 
that decreased bladder compliance is a risk factor for ther-
apy failure (LE 3, GR C).37 Moreover, it has been reported 
that the efficacy of onabotulinumtoxinA injections in pa-
tients with low bladder compliance has a shorter duration 
(12–24 weeks) than in those with normal compliance.40
Age
Komesu et al. compared the efficacy and adverse events 
of onabotulinumtoxinA injections in women <65 and ≥65 
years suffering from refractory urgency urinary inconti-
nence (LE 1, GR B).41 Even though the authors showed 
that both older and younger women experienced benefi-
cial reductions in urgency urinary incontinence episodes, 
similar rates of  adverse events and  improved quality 
of  life, the study revealed that younger women experi-
enced greater absolute continence, symptom improvement 
and fewer urinary tract infections. Women <65 years had 
3.3-fold greater odds of ≥75% symptom resolution than 
women ≥65 years (95% CI = 1.56–7.02). Compatible re-
sults were presented by Cohen et al., but the relationship 
was not statistically significant in a multivariate analysis 
(LE 1, GR B).42 Lower long-term success rates have also 
been noted in frail elderly patients (LE 2, GR B).43
Sex
Hsiao et al. showed that male gender is an  indepen-
dent factor associated with OAB treatment failure (LE 2, 
GR B).44 The study included a total of 89 patients (46 men 
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and 43 women) and found that female gender (OR = 3.75) 
was an  independent factor associated with treatment 
success.
Symptoms
It  has been shown that  low baseline OAB symptom 
scores and the presence of OAB wet are independent fac-
tors associated with therapeutic efficacy (LE 2, GR B).44 
The authors also found that high OAB symptom scores 
were an independent factor for predicting low response, 
but the coefficient was low (i.e. −0.12). Thus, symptoms 
of OAB (other than incontinence) seem to be a poor predic-
tor for assessing efficacy compared to simple evaluation 
of the presence or absence of incontinence.
Previous anticholinergic treatment
Makovey et al. reported that patients with poor antimus-
carinic efficacy experienced less therapeutic effect from 
onabotulinumtoxinA injections (LE 3, GR C).45 Success 
rates were lower in patients reporting a lack of efficacy 
of antimuscarinic drugs (34 of 57, 68%), compared to those 
who stopped because of side effects (24 of 28, 86%). In con-
trast, a pooled analysis of 2 trials of 100 U of onabotu-
linumtoxinA showed no difference in treatment effect 
irrespective of the number of antimuscarinic preparations 
tried, or whether oral medication was stopped due to side 
effects or a lack of efficacy (LE 1, GR B).46
Repeated injections
As  the  effects of  onabotulinumtoxinA therapy are 
of limited duration, patients usually require further treat-
ments. A recently published study suggested that in OAB 
patients who respond to  the  treatment, the  duration 
of the response declines after the 5th injection, suggesting 
a possible tolerance effect and a subsequent decline in ef-
ficacy (LE 3, GR C).47 The mean time between patients 
receiving intra-detrusor onabotulinumtoxinA and being 
added to the surgical waiting list for retreatment var-
ied between 8.5 and 10.4 months for the first 5 cycles 
of treatment, with the longest time period between the 3rd 
and 4th cycle. It then decreased to 5.5 and 5.25 months 
between the 5th and 6th cycle and between the 6th and 7th 
cycle of treatment, respectively. Further data extrapola-
tion has shown that at the 9th or 10th treatment, the mean 
duration of response to the treatment would be less than 
the recommended 4 months. The authors also proposed 
that treatments with symptomatic benefit of less than 3 
months should be regarded as “treatment failure”, i.e., 
patients who undergo further treatments with onabotu-
linumtoxinA may not get a sufficient therapeutic ben-
efit to justify repeating the procedure. These results are 
similar to those presented by Tincello et al., who found 
an increased rate of symptom recurrence following 2nd 
and 3rd treatments when compared to symptom recur-
rence after the 1st treatment (LE 3, GR C).48 Marcelissen 
et al. showed that almost 70% of all patients abandoned 
repeated treatments after a mean follow-up of 97 months 
(LE 3, GR C).49 Of the patients included (n = 128), 27% 
experienced insufficient effect and 43% had tolerance 
issues.
There have been 2 studies investigating the efficacy 
of repeated injections in neurogenic individuals in terms 
of risk factors for treatment failure. A recent study by De-
nys et  al. have showed that  patients with NDO with 
a ≥50% reduction of urinary incontinence after their 1st 
onabotulinumtoxinA treatment continued to  experi-
ence consistent improvements in urinary incontinence 
and quality of life with subsequent treatments over a pe-
riod of 4 years (LE 2, GR B).50 Initial positive responses 
were generally maintained to the same extent after repeat 
treatments. A <50% reduction of urinary incontinence 
after the 1st treatment did not necessarily predict low 
response with subsequent treatments, as more than 1/3 
of the patients with poor initial response showed bet-
ter results and  increasing response with subsequent 
injections. The  authors concluded that  these  results 
underscore the importance of attempting at  least a 2nd 
treatment with onabotulinumtoxinA before deeming 
neurogenic patients unsuitable for  this therapy. Jous-
sain et al. in their retrospective analysis of 292 patients, 
reported a failure rate of 12.6% (8.6–16.5%) after 3 years, 
22.2% (16.6–27.3%) after 5 years and 28.9% (21.9–35.3%) 
after 7 years of  follow-up, whereas the primary failure 
ratio was 5.1% (n = 15; LE 3, GR C).37
Other factors
In  neurogenic patients, other possible risk factors 
that may predict treatment failure include a high number 
of febrile urinary tract infections (LE 3, GR C) and kidney 
ultrasound abnormalities (LE 3, GR C).37
In OAB patients, smoking status has been found to be 
a predictive factor for non-response in urgency episodes 
(with smokers having nearly 3 times greater odds of non-
response compared to non-smokers), and higher num-
bers of baseline leakage episodes are correlated with fail-
ure to achieve continence (for every additional increase 
in the number of baseline leakage episodes, patients had 
a 17% increase in  the odds of  failing to achieve conti-
nence; LE 1, GR B).51 Body mass index (BMI) has been 
shown to have marginal associations with non-response 
to the treatment. It is worth noting that the risk factors 
identified in the study were derived from OAB women 
treated with 200 U of onabotulinumtoxinA and urody-
namically proven detrusor overactivity. Furthermore, 
the authors assessed potential patient factors correlated 
with non-response only at 6 weeks after treatment. Urinary 
tract infections in OAB patients were not found to affect 
the outcomes of the treatment (LE 1, GR B).51
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Predictive factors for CIC
There are no  universally accepted predictive factors 
for the need for CIC following injections of onabotulinum-
toxinA. However, the reported rates of CIC use seem to de-
pend on the etiology of detrusor overactivity, the injected 
dose along with the  injection technique, the definition 
of significant post-void residual urine, and other factors. 
It has been shown that the risk of post-treatment retention 
requiring CIC can be 2-fold higher in neurogenic patients 
than in those with OAB (LE 2, GR B).52 The affected neural 
mechanism for voiding in neurogenic individuals has been 
proposed as a reason for this phenomenon. The majority 
of available studies observed a dose-response relationship 
in terms of initiating CIC following onabotulinumtoxinA 
injections (LE 1, GR A).23,26,35 Currently recommended dos-
es (200 U in NDO, 100 U in OAB) represent an appropriate 
balance between the benefits and safety profile of the drug. 
A meta-analysis of efficacy and adverse events after trigonal 
vs extratrigonal injections revealed that trigonal injections 
were more often associated with acute urinary retention, 
but this correlation was not statistically significant.53 Tri-
gonal injections also lead to non-significantly higher values 
of post-void residual urine. The post-void residual (PVR) 
volume at which patient should start CIC varies among 
the available studies. Proposed cut-offs include 100 mL, 
150 mL, 200 mL, or even 300 mL.14,15,35,52,54 To make mat-
ters even more complex, the symptoms associated with 
retention have not always been included in the study defi-
nitions of significant retention. There are no strict criteria 
for CIC cessation, thus the duration of CIC may have been 
overestimated in some studies. Finally, a recent study has 
shown that CIC initiated on the basis of an arbitrary PVR 
volume does not benefit the patient, and CIC use should 
be based on  the  individual patient’s symptoms (LE  3, 
GR B/C).55 Nevertheless, a peak effect and dose-depen-
dent mean increase in PVR volume following onabotu-
linumtoxinA treatment is usually observed at week 2, with 
a gradual decrease between weeks 4 and 12 (LE 1, GR A).17,24 
Furthermore, the duration of catheterization (by CIC or in-
dwelling catheter) is typically longer with higher injected 
doses.17 The need for CIC also depends on the patient’s 
medical history of previous injections. On the one hand, 
patients who do not need CIC after their first injection are 
at a lower risk of needing CIC in later treatment cycles (LE 1, 
GR A).56 On the other hand, clinicians should remember 
that if CIC is necessary after the first injection, it seems 
to be needed after all subsequent treatments (LE 2, GR B).54 
In patients with a preoperative PVR volume >100 mL, re-
tention may appear in up to 95% of patients (LE 3, GR C).57 
Similar findings have been demonstrated in terms of low 
voiding efficiency (<90% of the voided volume compared 
to the pre-void bladder volume) (LE 3, GR C).58 Further-
more, it has been shown that patients with low maximum 
flow rates (<15 mL/s), low projected isovolumetric pres-
sure (<50, calculated as the maximum urinary flow rate 
+ detrusor pressure at the maximum urinary flow rate 
in women) and low bladder contractility index (<120, cal-
culated as 5 times the maximum urinary flow rate + de-
trusor pressure at the maximum urinary flow rate in men) 
are at increased risk of needing CIC after onabotulinum-
toxinA injections (LE 3, GR C).59 Clean intermittent cath-
eterization may also become necessary after later injections 
even if it was not initially required. Other factors that may 
increase the risk of CIC include older age (>61–76 years) 
(LE 2, GR B),43,60 frailty (LE 2, GR B)43 and higher parity 
(particularly a higher number of vaginal deliveries; LE 2, 
GR B).60 A recent study has shown that BMI and concomi-
tant comorbidities do not significantly influence PVR vol-
umes and the risk of CIC, even though one would expect 
that these factors could provoke safety issues.60 Neverthe-
less, Wang et al. showed that patients with diabetes have 
a significantly increased incidence of PVR volumes greater 
than 150 mL (60.4%) compared with nondiabetic patients 
(33.3%; LE 3, GR C).61
Although it may sometimes be necessary to introduce 
CIC, studies have shown that the need to perform CIC do 
not negatively impact the outcome of onabotulinumtoxinA 
therapy, and that  improvements in patients’ symptoms 
are similar with and without CIC.31,57 It has been shown 
that the risk of new-onset urine retention with a need 
for CIC usually disappears 2 weeks after the injections.60
Discussion
To the best of our knowledge, this is the first study sum-
marizing reported methods of efficacy assessment and fac-
tors predicting failure in onabotulinumtoxinA therapy. 
Currently, onabotulinumtoxinA is the only formulation 
of botulinum toxin that has been investigated in properly 
powered, multicenter, multinational randomized controlled 
trials, and only onabotulinumtoxinA is licensed in the USA 
and Europe for the management of NDO and OAB.
Our study revealed that most of the randomized con-
trolled trials investigating the efficacy of intra-detrusor in-
jections with onabotulinumtoxinA, both in OAB and NDO 
patients, commonly used the  number of  incontinence 
episodes as the primary experimental outcome. However, 
this parameter cannot be directly applied in daily clini-
cal practice, as it is not always well correlated with sub-
jective outcomes, including health-related quality of life, 
treatment satisfaction, subjective assessments of global 
“improvement”, or the safety of the upper urinary tract.20
As OAB is a syndrome in the absence of urinary tract 
infection or  other obvious pathology, outcomes from 
treatment are subjective, highly individual and influenced 
by patients’ lifestyle as well as their expectations from 
treatment. As the patient’s perception of treatment suc-
cess in OAB is an important component of overall success, 
clinicians should keep in mind that they underestimate 
the extent to which patients are affected by their symptoms 
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in 25–37% of cases.62 Therefore, reports of medical out-
comes after treatment should always include independent, 
validated questionnaires self-administered by patients 
to avoid interviewer bias.63 Furthermore, it has been dem-
onstrated that objective measures from bladder diaries have 
correlated poorly with patient-related outcome measures, 
suggesting that objective and subjective assessments mea-
sure different aspects of treatment efficacy.64 Therefore, 
any evaluation of the efficacy of intra-detrusor injections 
with onabotulinumtoxinA in day-to-day clinical treatment 
of OAB patients should be based on objective measures 
(from bladder diaries) as well as patient-reported outcomes 
(from questionnaires). The  International Consultation 
on Incontinence has evaluated specific criteria for current-
ly used questionnaires and developed a recommendation 
grading system. Questionnaires with a Grade A recom-
mendation (highly recommended) should be used in clini-
cal practice. Among them are the Overactive Bladder Ques-
tionnaire (OAB-q), the Overactive Bladder Satisfaction 
Questionnaire (OAB-S), the Overactive Bladder Symptom 
Scores Questionnaire (OABSS), the Incontinence Impact 
Questionnaire (II-Q), and the Urogenital Distress Inven-
tory (UDI). Nowadays, single-question questionnaires 
(e.g., the Patient Global Impression Scale, the Treatment 
Benefit Scale, the Likert scale, and VAS score65) are be-
coming more popular and are widely used in daily prac-
tice. The lack of a positive change in these scales following 
treatment could be used to define treatment failure. Each 
questionnaire can be used alone or in combination with 
other questionnaires to improve assessment or monitoring 
of treatment outcomes.4 Some experts suggest that in daily 
clinical practice, treatment outcomes in OAB patients can 
be judged by patient communication regarding chang-
es in their symptoms or improvements in their quality 
of life, without objective documentation. In our opinion, 
this practice should be avoided. Assessment of treatment 
efficacy with urodynamics in OAB patients is not currently 
recommended, as a recently published systematic review 
with meta-analysis has shown that urodynamic parameters 
may not differ despite significant improvement in patient-
oriented outcomes.2 Current guidelines advise that follow-
up should be patient/symptom directed and a new injection 
may be considered when the clinical benefit of the previ-
ous injection diminishes, but a period of 3 months must 
elapse between each injection.66 Also, the manufacturer 
of onabotulinumtoxinA recommends that retreatment 
should not be considered within 12 weeks from the previ-
ous bladder injection, and the total dose should not exceed 
360 U in a 3-month period for all indications.67
There are no guidelines or recommendations available 
for following up neurogenic patients treated with intra-
detrusor onabotulinumtoxinA injections. As neurological 
diseases are usually progressive, videourodynamic study 
and the use of validated questionnaires with a bladder diary 
at baseline are recommended. The primary goal of blad-
der management in  neurogenic patients is  to  achieve 
low-pressure urine storage and  low-pressure emptying 
of the bladder. Thus, the therapy should be assessed with 
a urodynamic study, even though available randomized 
controlled trails used changes in the frequency of urinary 
incontinence episodes as a primary experimental outcome. 
In high-risk patients (i.e., those with vesicoureteral reflux, 
elevated detrusor pressures, decreased bladder compliance, 
and worsening hydronephrosis or renal function), experts 
recommend repeating urodynamic studies after injections 
regardless of the clinical outcome.68 In the current literature, 
there is a tendency to define unsuccessful treatment with 
maximum storage pressure >40 cm H2O and/or detrusor 
compliance <20 mL/cm H2O after injections. Moreover, 
it has been proposed that the following parameters should 
be recorded: the presence of involuntary detrusor contrac-
tions, the volume of bladder filling at the first involuntary 
contraction, the maximum detrusor pressure of involuntary 
contractions of greater intensity, the maximum cystomet-
ric capacity, the first voiding desire, bladder compliance, 
maximum detrusor pressure, maximum flow, detrusor pres-
sure at maximum flow, and post-void residual volume.69 
In low-risk patients (i.e., those with low detrusor storage 
pressures and appropriate compliance, and when other clini-
cal evaluations also suggest stable lower and upper urinary 
tracts in a non-progressive neurologic disease), urodynamic 
studies after injections can be delayed if the patient responds 
clinically to the treatment.68
Our study revealed that possible risk factors that may in-
fluence treatment outcomes include urodynamically proven 
detrusor overactivity (LE 1, GR D), elevated maximum de-
trusor pressure (LE 1, GR B/C), greater maximum cystomet-
ric capacity (LE 2, GR B/C), impaired bladder compliance 
(LE 2, GR B), older age (LE 1, GR B), male gender (LE 2, 
GR B), higher bother score from symptoms at baseline (LE 2, 
GR B), previous anticholinergic treatment (LE 3, GR D), 
repeated injections with a subsequent decline in efficacy 
(LE 3, GR C), and other factors (LE 2/3, GR B/C). Patients 
with these risk factors should be informed that they may 
experience less efficacy. It might be suggested that the pre-
dictors of success identified by our study may vary depend-
ing on treatment dose, but it has recently been emphasized 
that there is no physiological or pharmacological reason why 
such a difference would exist.51
In patients who did not respond to the treatment, other 
potential underlying disorders for the symptoms reported 
should be taken into account. It  is noteworthy that pa-
tients with OAB symptoms may in fact suffer from pain-
ful bladder or interstitial cystitis; these individuals appear 
to respond less favorably to with onabotulinumtoxinA,70 
and if the treatment is effective, it has a shorter duration 
of action.71 In patients with decreased bladder compliance, 
special attention should be given to any possible underly-
ing neurological disorders, as impaired compliance is usu-
ally a sequela of neurologic disease, but it may also result 
from any process that destroys the elastic or viscoelastic 
properties of the bladder wall. In neurogenic patients, failed 
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treatment may also result from progression of their under-
lying neurological disorder. Physicians should remember 
that short duration of efficacy or treatment failure can be 
dependent upon procedure-related factors, such as problems 
with the storage of onabotulinumtoxinA vials, the recon-
stitution process or the injection technique. Optimization 
of the injection procedure (the first indication; dose person-
alization depending on clinical and urodynamic parameters, 
but also patient expectations; injection localization) could 
help improve the global efficacy of onabotulinumtoxinA 
treatment. Moreover, associated urinary tract infections can 
mask effective treatment. Development of neutralizing anti-
bodies against the neurotoxin is possible, but very unlikely. 
It has been demonstrated that <1% of patients develop neu-
tralizing antibodies to onabotulinumtoxinA after treatment 
cycle 6 and their presence has no significant impact on treat-
ment efficacy.23,72 Another hypothesis to explain treatment 
failure could be histological modifications induced by injec-
tions. However, studies have demonstrated no difference 
in terms of inflammation, fibrosis or edema before and after 
1 or multiple injections.73 Moreover, no histological differ-
ences were found between responders and non-responders. 
Patients for whom the treatment failed should be questioned 
with regard to changes in lifestyle or the use of new medica-
tions that may have contributed to the worsening of lower 
urinary tract symptoms.
If the treatment fails and/or a physician predicts that in-
tra-detrusor injections of onabotulinumtoxinA might be 
ineffective, a switch to a different toxin seems to be more 
effective than administering another injection of the same 
toxin. Replacing onabotulinumtoxinA with abobotulinum-
toxinA may provide satisfying results.74 It has been also 
proposed that in non-responding patients planned for re-
peated injections, the dose may be increased by an extra 
50 U in OAB and an extra 100 U in NDO individuals.69
Some studies describe a phenomenon called “secondary 
failure”. This term is used for patients who responded well 
to the first injection(s), but eventually had very limited 
benefit after subsequent treatments. Possible causes in-
clude an underlying immunological mechanism (antibody 
formation) or a technical issue with subsequent injections 
(less adequate delivery). Therefore, some experts have 
proposed that a repeat injection at least 3 months after 
the failed injection should be performed in patients with 
secondary failure.75
Conclusions
In  conclusion, onabotulinumtoxinA is  well estab-
lished as a second-line treatment for patients with OAB 
and NDO. When following up OAB patients treated with 
onabotulinumtoxinA, a validated questionnaire should 
be used to measure the degree of symptom bother, while 
a voiding diary should be utilized to assess the response 
to the treatment. In neurogenic individuals, the therapy 
should be also evaluated with a urodynamic study. Pa-
tients with risk factors for treatment failure should be 
appropriately informed of the possible lack of efficacy. 
This article can serve as a reference document for  fu-
ture research assessing the efficacy of onabotulinum-
toxinA in specific clinical situations and help urologists 
select appropriate patients and evaluate their response 
to the treatment.
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